VITEK PRO
bioMérieux, Inc. · Decision date Nov 3, 2026
What did the FDA decide?
FDA recorded a substantial equivalence decision (SESE) for VITEK PRO, submitted by bioMérieux, Inc. under 510(k) number K262683, with a decision date of 2026-11-03. The product code is LON and the listed specialty is microbiology. The record describes the VITEK PRO as an automated diagnostic system for identification and antimicrobial susceptibility testing, and as in vitro diagnostic test software for those purposes.
The available excerpts state that the submitted information in the premarket notification is complete and supports a substantial equivalence decision, so this is a 510(k) clearance rather than a PMA approval. The excerpts also reference the Advanced Expert System for online validation of results and interpretation of resistant phenotypes, and note that quality control should follow the package insert protocol for each AST card and antimicrobial agent. The record does not identify a prior predicate device, the specific cleared test menu, or the full indications for use.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Nov 3, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262683
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- bioMérieux, Inc.
- Product code
- LON
- Decision code
- SESE
- Decision date
- Nov 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Test, Automated, Antimicrobial Susceptibility, Short Incubation.
- Applicant
- bioMérieux, Inc.
- Product code
- LON
- FDA device class
- 2
FDA decision timeline
K262683 received
Application receipt date recorded by FDA.
K262683 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LON
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| BIOMERIEUX, Inc. | 510(k) clearance | Nov 4, 2026 | FDA | |
| BIOMERIEUX, Inc. | 510(k) clearance | Oct 1, 2026 | FDA | |
| bioMérieux, Inc. | 510(k) clearance | Sep 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
bioMérieux, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hazelwood, MO
Sources and methodology
- Original FDA record: K262683
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
